High-dose chemotherapy and autologous stem cell rescue for metastatic breast cancer: Superior survival for tandem compared with single transplants

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 28, Issue 3, 2005, Pages 281-288

  Dillman, Robert O ^a   Barth, Neil M ^a   VanderMolen, Louis A ^a   Allen, Kanoe ^a   Beutel, Linda D ^a   Chico, Sherri ^a  

^a HOAG MEMORIAL HOSPITAL PRESBYTERIAN   (United States)

Author keywords

High dose chemotherapy; Metastatic breast cancer; Tandem stem cell transplants

Indexed keywords

CARBOPLATIN; ETOPOSIDE; IFOSFAMIDE; MITOXANTRONE; THIOTEPA;

ADULT; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BONE METASTASIS; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; FEMALE; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; METASTASIS; SINGLE STEM CELL TRANSPLANTATION; TANDEM STEM CELL TRANSPLANTATION;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; CARBOPLATIN; COHORT STUDIES; DISEASE-FREE SURVIVAL; ETOPOSIDE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IFOSFAMIDE; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; MITOXANTRONE; ORGAN SPECIFICITY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; THIOTEPA; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 20444378500     PISSN: 02773732     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.coc.0000156917.43490.65     Document Type: Article

References (39)

1. Cold S, Jensen NV, Brincker H, et al. The significance of chemotherapy for survival after recurrent breast cancer: a population based study of patients treated in the 1950's, 1960's and 1970's. Ugeskr Laeger. 1994;156:6507-6511.
2. Sledge GW, Antman KH. Progress in chemotherapy for metastatic breast cancer. Semin Oncol. 1992;19:317-332.
3. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol. 1984;2:1281-1288.
4. Hryniuk W, Levine MN. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol. 1986;4:1162-1170.
5. Henderson IC, Hayes DF, Gelman R. Dose-response in the treatment of breast cancer: a critical review. J Clin Oncol. 1988;6:1501-1515.
6. O'Shaughnessy JA, Cowan KH. Dose-intensive therapy for breast cancer. JAMA. 1993;270:2089-2092.
7. Wood WC, Budman DR, Korzun AH, et al. Dose and intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med. 1994;330:1253-1258.
8. Budman DR, Berry DA, Cirrincione CT, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst. 1998;90:1205-1211.
9. Norton L, Simon R. Tumor size, sensitivity to therapy and the design of treatment schedules. Cancer Treat Rep. 1977;61:1307-1317.
10. Goldie J, Coldman AJ. A mathematical model for relating drug sensitivity of tumors to their spontaneous mutation rate. Cancer Treat Rep. 1979;63:1727-1773.
11. Peters WP, Shpall EJ, Jones RB, et al. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988;6:1368-1376.
12. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. N Engl J Med. 2000;342:1069-1076.
13. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol. 1995;13:2483-2489.
14. Weiss RB, Rifkin RM, Stewart FM, et al. High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study. Lancet. 2000;355:999-1003.
15. Weiss RB, Gill GG, Hudis CA. An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications. J Clin Oncol. 2001;19:2771-2777.
16. Dillman RO, Barth NM, Nayak SK, et al. High-dose chemotherapy with autologous stem cell rescue in breast cancer. Breast Cancer Res Treat. 1996;37:277-289.
17. Singletary SE, Allred C, Ashley P, et al. Revision of the American Joint Committee on Cancer staging system for breast cancer. J Clin Oncol. 2002;20:3628-3636.
18. Weaver CH, Hazelton B, Birch R, et al. An analysis of engraftment kinetics as a function of the CD34 content of peripheral blood progenitor cell collections in 692 patients after the administration of myeloablative therapy. Blood. 1995;86:3961-3969.
19. Stadtmauer EA, Schneider CJ, Silberstein L. Peripheral blood progenitor cell generation and harvesting. Semin Oncol. 1995;22:291-300.
20. Jones RB, Shpall EJ, Shogan J, et al. The Duke AFM program, intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990;66:431-436.
21. Pecora AL, Lazarus HM, Stadtmauer EA, et al. Effect of induction chemotherapy and tandem cycles of high-dose chemotherapy on outcomes in autologous stem cell transplant for metastatic breast cancer. Bone Marrow Transplant. 2001;27:1245-1253.
22. Schmitz N, Linch DC, Dreger P, et al. Randomised trial of filgrastim-mobilized peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patients. Lancet. 1996;347:353-357.
23. Pecora AL, Lazarus HM, Jennis AA, et al. Breast cancer cell contamination of blood stem cell products inpatients with metastatic breast cancer: predictors and clinical relevance. Biol Blood Marrow Transplant 2002;8:536-543.
24. Akard LP, Thompson JM, Dugan MF, et al. Matched-pair analysis of hematopoietic progenitor cell mobilization using G-CSF vs. cyclophosphamide, etoposide, and G-CSF: enhanced CD34+ cell collections are not necessarily cost-effective. Biol Blood Marrow Transplant. 1999;5:379-385.
25. Koc ON, Gerson SL, Cooper BW, et al. Randomized cross-over trial of progenitor-cell mobilization: high-dose cyclophosphamide plus granulocyte colony-stimulating factor (G-CSF) versus granulocyte-macrophage colony-stimulating factor plus G-CSF. J Clin Oncol. 2000;18:1824-1830.
26. Bishop JF. Current experience with high-dose carboplatin therapy. Semin Oncol. 1992;19(suppl 2):50-154.
27. Fields KK, Elfenbein GJ, Perkins JB, et al. Two novel high-dose treatment regimens for metastatic breast cancer-ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities. Semin Oncol. 1993;20(suppl 6):59-66.
28. Williams SF, Gilewski T, Mick R, et al. High-dose consolidation therapy with autologous stem-cell rescue in stage IV breast cancer: follow-up report. J Clin Oncol. 1992;10:1742-1747.
29. Ayash LJ, Elias A, Schwartz G, et al. Double dose-intensive chemotherapy with autologous stem-cell support for metastatic breast cancer: no improvement in progression-free survival by the sequence of high-dose melphalan followed by cyclophosphamide, thiotepa, and carboplatin. J Clin Oncol. 1996;14:2984-2992.
30. Kennedy MJ, Beveridge RA, Rowley SD, et al. High-dose chemotherapy with reinfusion of purged autologous bone marrow following dose-intense induction as initial therapy for metastatic breast cancer. J Natl Cancer Inst. 1991;83:920-925.
31. Dunphy FR, Spitzer G, Buzdar AU, et al. Treatment of estrogen receptor-negative or hormonally refractory breast cancer with double high-dose chemotherapy intensification and bone marrow support. J Clin Oncol. 1990;8:1207-1216.
32. Antman K, Ayash L, Elias A, et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol. 1992;10:102-110.
33. Hu WW, Negrin RS, Stockerl-Goldstein K, et al. Four-cycle high-dose therapy with hematopoietic support for metastatic breast cancer: no improvement in outcomes compared with single-course high-dose therapy. Biol Blood Marrow Transplant. 2000;6:58-69.
34. Broun ER, Sridhara R, Sledge GW, et al. Tandem autotransplantation for the treatment of metastatic breast cancer. J Clin Oncol. 1995;13:2050-2055.
35. Vahdat LT, Balmaceda C, Papadopoulos K, et al. Phase II trial of sequential high-dose chemotherapy with paclitaxel, melphalan and cyclophosphamide, thiotepa and carboplatin with peripheral blood progenitor support in women with responding metastatic breast cancer. Bone Marrow Transplant. 2002;30:149-155.
36. Berry DA, Broadwater G, Klein JP, et al. High-dose versus standard chemotherapy in metastatic breast cancer: comparison of Cancer and Leukemia Group B trials with data from the Autologous Blood and Marrow Transplant Registry. J Clin Oncol. 2002;20:743-750.
37. Somlo G, Doroshow JH, Forman SJ, et al. High-dose cisplatin, etoposide, and cyclophosphamide with autologous stem cell reinfusion in patients with responsive metastatic or high-risk primary breast cancer. Cancer. 1994;73:125-134.
38. Ghalie R, Williams S, Valentino LA, et al. Tandem peripheral blood progenitor cell transplants as initial therapy for metastatic breast cancer. Biol Blood Marrow Transplant. 1995;1:40-46.
39. Antman KH, Rowlings PA, Vaughan WP, et al. High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol. 1997;15:1870-1879.